Cargando…

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study

Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism. This analysis reports changes in late-night salivary cortisol (LNSC) during a 12-month, multicentre, Phase III study of patients with Cushing’s disease who we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Findling, James W., Fleseriu, Maria, Newell-Price, John, Petersenn, Stephan, Pivonello, Rosario, Kandra, Albert, Pedroncelli, Alberto M., Biller, Beverly M. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083774/ https://www.ncbi.nlm.nih.gov/pubmed/27209465 http://dx.doi.org/10.1007/s12020-016-0978-6

Ejemplares similares

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease
por: Petersenn, S, et al.
Publicado: (2014)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome
por: Kannankeril, Joshua, et al.
Publicado: (2020)

MON-172 Comparison of a Late-night Salivary Cortisol Immunoassay and a Cortisol and Cortisone LCMS Assay in Patients with Cushing’s Disease
por: Kannankeril, Joshua, et al.
Publicado: (2020)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Late-night salivary cortisol and cortisone should be the initial screening test for Cushing’s syndrome
por: Mohamed, Ramjan Sanas, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
por: Fleseriu, Maria
Publicado: (2020)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
por: Schopohl, Jochen, et al.
Publicado: (2014)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
por: Fleseriu, Maria, et al.
Publicado: (2013)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bjfc1ltpj2tsfrh780drs425d8